Abstract
Despite the advantages of second‐generation antipsychotics, effectiveness trials and cost‐effective analyses have caused first‐generation antipsychotics to be reexamined with regard to place in therapy. Developing an understanding of all aspects of first‐generation antipsychotics, including the pharmacokinetic complexity of long‐acting decanoate formulations, are essential for practitioners in order to optimally manage both symptoms and adverse events. We describe a 55‐year‐old schizophrenic man with a severe movement disorder whose symptoms were mistaken for lithium toxicity. Further examination revealed that his fluphenazine plasma level was still detected 4 months after his last dose of fluphenazine decanoate had been administered. The incorrect diagnosis of lithium toxicity resulted in delayed treatment of his severe extrapyramidal symptoms. Administration of a routine dosage of benztropine titrated to 4 mg/day resolved his drug‐induced movement disorder within 72 hours. This case report demonstrates the persistent need for practitioners' awareness of the complex pharmacokinetic properties of long‐term fluphenazine decanoate treatment, resulting in prolonged absorption, and the continued importance of both recognizing adverse events resulting from dopamine D2‐receptor antagonism and developing the ability to distinguish between various types of movement disorders. The potential for increasing use of first‐generation antipsychotics highlights the need to revisit the nuances of long‐acting, injectable pharmacokinetics to improve patient outcomes.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.